When breast cells divide and multiply out of control, it is called breast cancer. Symptoms
include lump formation in the breast, a change in the texture or color of the breast, or a discharge from
the nipple. Local or systemic therapy is frequently used to treat breast cancer. Surgical and radiation
procedures limited to the affected area are examples of local management. There has been significant
worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first
therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist the expansion of
cancer cells by inducing the destruction of cellular membranes, blocking immune system inhibitors, and
preventing the formation of new blood vessels. mAbs can also target growth factor receptors. Understanding the molecular pathways involved in tumor growth and its microenvironment is crucial for developing effective targeted cancer therapeutics. Due to their unique properties, mAbs have a wide range
of clinical applications. Antibody-drug conjugates (ADCs) are drugs that improve the therapeutic index
by combining an antigen-specific antibody with a payload. This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like
trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The
creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multispecific antibodies, must be a central focus of future studies. This review will help scientists working on
developing mAbs to treat cancers more effectively